Drug profile · INN
asparaginase erwinia chrysanthemi (recombinant)-rywn
RYLAZE
asparaginase erwinia chrysanthemi (recombinant)-rywn (RYLAZE) is a asparagine hydrolytic enzyme. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — asparaginase erwinia chrysanthemi (recombinant)-rywn
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR
- Patents
- 8
- Programs
- 4
- Data quality
- 0.89
Quick answer
asparaginase erwinia chrysanthemi (recombinant)-rywn (RYLAZE) is a asparagine hydrolytic enzyme. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Asparagine hydrolytic enzyme
Primary target: Asparagine
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11413264
Carbamoyl phenylalaninol analogs and uses thereof
granted -
US 11149000
Carbamoyl phenylalaninol compounds and uses thereof
granted -
US 10710958
Carbamoyl phenylalaninol compounds and uses thereof
granted -
US 9707270
Method for administering ω-conopeptide
granted -
US 9555017
Methods of making a mixture of salts of gamma-hydroxybutyrate
granted -
US 8765680
Method for administering omega-conopeptide
granted -
US 8653033
Method for administering omega-conopeptide
granted -
US 8609651
Pharmaceutical compositions of benzodiazepines and method of use thereof
granted
Frequently asked questions
What is asparaginase erwinia chrysanthemi (recombinant)-rywn?
asparaginase erwinia chrysanthemi (recombinant)-rywn (RYLAZE) is a asparagine hydrolytic enzyme. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for asparaginase erwinia chrysanthemi (recombinant)-rywn?
RYLAZE is a marketed brand name for asparaginase erwinia chrysanthemi (recombinant)-rywn. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of asparaginase erwinia chrysanthemi (recombinant)-rywn?
asparaginase erwinia chrysanthemi (recombinant)-rywn has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.